- Adjunctive management of primary hypercholesterolemia and mixed dyslipidemias.
- Adjunctive management of hypertriglyceridemia.
- Adjunctive management of primary dysbetalipoproteinemia.
- Homozygous familial hypercholesterolemia.
- Slows the progression of atherosclerosis as adjunct to diet.
- Adjunctive therapy to diet and exercise for the reduction of LDL cholesterol in children 8–17 yrs with heterozygous familial hypercholesterolemia if after diet therapy fails the following still exist: LDL cholesterol remains >190 mg/dL or remains >160 mg/dL [with family history of premature cardiovascular disease or
2 risk factors for cardiovascular disease]) - Primary prevention of cardiovascular disease (reduces risk of stroke, myocardial infarction, and revascularization) in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease because of age (50 yr for men; 60 yr for women), hsCRP 2 mg/L, and the presence of 1 risk factor for cardiovascular disease (hypertension, low HDL-C, smoking, or premature family history of coronary heart disease).
